[go: up one dir, main page]

MX2015009055A - Forma de dosificacion oral de liberacion sostenida gastro retentiva de un secuestrante de acido biliar. - Google Patents

Forma de dosificacion oral de liberacion sostenida gastro retentiva de un secuestrante de acido biliar.

Info

Publication number
MX2015009055A
MX2015009055A MX2015009055A MX2015009055A MX2015009055A MX 2015009055 A MX2015009055 A MX 2015009055A MX 2015009055 A MX2015009055 A MX 2015009055A MX 2015009055 A MX2015009055 A MX 2015009055A MX 2015009055 A MX2015009055 A MX 2015009055A
Authority
MX
Mexico
Prior art keywords
bile acid
acid sequestrant
agonists
gastro
dosage form
Prior art date
Application number
MX2015009055A
Other languages
English (en)
Other versions
MX383752B (es
Inventor
Vasu Sethuraman
David Bruce Hedden
Kristen Marie Leskow
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MX2015009055A publication Critical patent/MX2015009055A/es
Publication of MX383752B publication Critical patent/MX383752B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente nuevas composiciones y métodos para controlar la liberación del secuestrante del ácido biliar al estómago con el fin de tratar o prevenir trastornos del tracto GI superior o trastornos de la garganta. Los métodos generalmente incluyen la administración a un paciente en tal necesidad de una cantidad terapéuticamente efectiva de una composición farmacéutica que comprende al menos un secuestrante del ácido biliar dispersado en una matriz polimérica. La composición del secuestrante del ácido biliar puede administrarse sola o en combinación con al menos un inhibidor de la bomba de protón, y opcionalmente uno o más agentes seleccionados de antiácidos, antagonistas del receptor H2 de histamina, agonistas de ?-ácido aminobutírico ß (GABA-B), profármacos de agonistas GABA-B, antagonistas de la bomba ácida, inhibidores de proteasa y agonistas GC-C.
MX2015009055A 2013-01-15 2014-01-14 Forma de dosificación oral de liberación sostenida gastro retentiva de un secuestrante de ácido biliar. MX383752B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752726P 2013-01-15 2013-01-15
US201361914804P 2013-12-11 2013-12-11
PCT/US2014/011450 WO2014113377A1 (en) 2013-01-15 2014-01-14 Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant

Publications (2)

Publication Number Publication Date
MX2015009055A true MX2015009055A (es) 2016-05-16
MX383752B MX383752B (es) 2025-03-11

Family

ID=50031605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009055A MX383752B (es) 2013-01-15 2014-01-14 Forma de dosificación oral de liberación sostenida gastro retentiva de un secuestrante de ácido biliar.

Country Status (12)

Country Link
US (6) US20160015644A1 (es)
EP (2) EP3991719A1 (es)
JP (2) JP6716255B2 (es)
CN (2) CN105338958A (es)
AU (1) AU2014207680B2 (es)
BR (1) BR112015016917B1 (es)
CA (1) CA2898362C (es)
EA (1) EA201591338A1 (es)
ES (1) ES2906114T3 (es)
HK (1) HK1214529A1 (es)
MX (1) MX383752B (es)
WO (1) WO2014113377A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015016917B1 (pt) * 2013-01-15 2022-08-30 Ironwood Pharmaceuticals, Inc Forma de dosagem oral de retenção gástrica, e, uso de um sequestrante de ácido biliar
CA2902348C (en) * 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
CN105362244A (zh) * 2015-11-26 2016-03-02 青岛海之源智能技术有限公司 考来烯胺缓释片及制备方法
CN105456219A (zh) * 2015-12-28 2016-04-06 青岛海之星生物科技有限公司 一种考来替泊缓释片及制备方法
CN105520919A (zh) * 2015-12-28 2016-04-27 青岛海之星生物科技有限公司 一种考来替泊缓释胶囊及制备方法
BR112019012689A2 (pt) * 2016-12-21 2019-11-19 Ironwood Pharmaceuticals Inc métodos de tratamento da síndrome do intestino irritável com formulações de linaclotide modificada ou de liberação prolongada
AU2018302255A1 (en) * 2017-07-19 2020-02-06 Ironwood Pharmaceuticals, Inc. Efficacy of a gastro-retentive bile acid sequestrant dosage form
CN111110647A (zh) * 2018-10-31 2020-05-08 浙江京新药业股份有限公司 含盐酸考来维仑的药物组合物及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS5692217A (en) 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4472409A (en) 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
AU545463B2 (en) 1982-06-25 1985-07-18 Kowa Co. Ltd. Benzoyl piperacine esters
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4738975A (en) 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
FI96860C (fi) 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
JP2916206B2 (ja) 1990-04-28 1999-07-05 帝國製薬株式会社 生理活性ペプチド
JP2916205B2 (ja) 1990-04-28 1999-07-05 帝國製薬株式会社 生理活性ペプチド
DK223790D0 (da) 1990-09-18 1990-09-18 Novo Nordisk As Proteaseholdig detergentkomposition
ATE191213T1 (de) 1990-10-17 2000-04-15 Takeda Chemical Industries Ltd Pyridin-derivate, verfahren zu deren herstellung und anwendung
US5167483A (en) 1990-12-24 1992-12-01 Gardiner Samuel W Method for utilizing angular momentum in energy conversion devices and an apparatus therefore
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
PL2124884T3 (pl) * 2006-12-22 2020-01-31 Ironwood Pharmaceuticals, Inc. Metody i kompozycje do leczenia zaburzeń przełyku
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
BR112015016917B1 (pt) * 2013-01-15 2022-08-30 Ironwood Pharmaceuticals, Inc Forma de dosagem oral de retenção gástrica, e, uso de um sequestrante de ácido biliar
CN103585128A (zh) * 2013-11-18 2014-02-19 北京泰德制药股份有限公司 一种包含盐酸考来维仑的药物组合物及其制备方法

Also Published As

Publication number Publication date
AU2014207680A1 (en) 2015-08-27
EP2945614A1 (en) 2015-11-25
EP3991719A1 (en) 2022-05-04
US20220370367A1 (en) 2022-11-24
US20160015644A1 (en) 2016-01-21
US20210267903A1 (en) 2021-09-02
HK1214529A1 (zh) 2016-07-29
CA2898362C (en) 2020-09-01
CA2898362A1 (en) 2014-07-24
JP6716255B2 (ja) 2020-07-01
JP2018203787A (ja) 2018-12-27
ES2906114T3 (es) 2022-04-13
NZ709924A (en) 2021-02-26
BR112015016917B1 (pt) 2022-08-30
AU2014207680B2 (en) 2018-09-06
JP6755920B2 (ja) 2020-09-16
WO2014113377A1 (en) 2014-07-24
CN108057028A (zh) 2018-05-22
US20220110876A1 (en) 2022-04-14
EP2945614B1 (en) 2021-11-24
CN105338958A (zh) 2016-02-17
EA201591338A1 (ru) 2016-01-29
US20210015754A1 (en) 2021-01-21
BR112015016917A2 (es) 2017-08-15
US20170266116A1 (en) 2017-09-21
MX383752B (es) 2025-03-11
JP2016508992A (ja) 2016-03-24

Similar Documents

Publication Publication Date Title
MX2015009055A (es) Forma de dosificacion oral de liberacion sostenida gastro retentiva de un secuestrante de acido biliar.
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
UY32925A (es) Composiciones de corticosteroides de administración oral
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
MX363007B (es) Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados.
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
AR059575A1 (es) Metodo para el tratamiento de enfermedades inflamatorias
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112017025664A2 (pt) composições e métodos para aumentar a neurogênese em animais
BR112015019264A2 (pt) composições farmacêuticas para o tratamento de helicobacter pylori
CL2011001132A1 (es) Metodo para reducir al minimo la inflamacion en el sitio de inyeccion durante la administracion subcutanea de una macromolecula que comprende agregar a una formulacion que contiene la macromolecula de 2% a 30% de ciclodextrina; formulacion que comprende un anticuerpo; y metodo para reducir al minimola precipitacion del anticuerpo.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
UY31097A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
AR061477A1 (es) Metodos para utilizar un derivado de tiazol
AR075345A1 (es) Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
DOP2013000004A (es) Agentes terapeuticos 976
MX349193B (es) Capsula con contenido liquido con un antiinflamatorio.
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
Lee et al. PS 0238; Gastroenterology: Cases of Ischemic Colitis Associated with Pseudoephedrine